Cullinan Therapeutics, Inc.
General ticker "CGEM" information:
- Sector: Health Care
- Industry: Medical - Pharmaceuticals
- Capitalization: $613.5M (TTM average)
Cullinan Therapeutics, Inc. follows the US Stock Market performance with the rate: 48.4%.
Estimated limits based on current volatility of 2.9%: low 16.62$, high 17.63$
Factors to consider:
- Earnings expected soon, date: 2026-08-06 bmo
- Total employees count: 109 (-1.8%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Clinical trial failure, Capital raising failure, Regulatory and compliance, Manufacturing disruptions, Labor/talent shortage/retention
- Current price 10.1% above estimated high
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [6.82$, 14.99$]
- 2026-12-31 to 2027-12-31 estimated range: [5.79$, 13.06$]
Financial Metrics affecting the CGEM estimates:
- Negative: with PPE of -3.0 at the end of fiscal year the price was high
- Negative: Operating cash flow per share per price, % of -29.19 <= 0.30
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 29.89 > -0.65
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of -1.30 <= -0.15
- Negative: Industry operating cash flow per share per price (median), % of 0.76 <= 5.54
- Negative: Shareholder equity ratio, % of 91.16 > 63.79
Short-term CGEM quotes
Long-term CGEM plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $191.09MM | $196.92MM | $241.65MM |
| Operating Income | $-191.09MM | $-196.92MM | $-241.65MM |
| Non-Operating Income | $21.87MM | $29.46MM | $21.77MM |
| R&D Expense | $148.16MM | $142.90MM | $187.40MM |
| Income(Loss) | $-169.22MM | $-167.46MM | $-219.88MM |
| Taxes | $-14.12MM | $0.12MM | $0.00MM |
| Net Income(Loss)* | $-153.16MM | $-167.38MM | $-219.88MM |
| Stockholders Equity | $453.70MM | $590.33MM | $408.73MM |
| Assets | $484.18MM | $621.82MM | $448.37MM |
| Operating Cash Flow | $-134.28MM | $-145.30MM | $-175.75MM |
| Capital expenditure | $0.21MM | $0.00MM | $0.05MM |
| Investing Cash Flow | $35.81MM | $-136.31MM | $179.99MM |
| Financing Cash Flow | $40.75MM | $266.19MM | $1.09MM |
| Earnings Per Share** | $-3.69 | $-3.11 | $-3.72 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.